Shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) rose 1.5% during mid-day trading on Tuesday . The company traded as high as $2.71 and last traded at $2.66. Approximately 144,413 shares changed hands during trading, a decline of 5% from the average daily volume of 151,846 shares. The stock had previously closed at $2.62.
Analyst Upgrades and Downgrades
A number of analysts have commented on IMMX shares. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a research note on Wednesday, June 4th. Wall Street Zen upgraded Immix Biopharma to a "hold" rating in a report on Friday, June 27th.
Get Our Latest Analysis on IMMX
Immix Biopharma Stock Down 2.0%
The company has a market capitalization of $74.01 million, a P/E ratio of -3.79 and a beta of 0.24. The business's 50-day moving average is $2.25 and its two-hundred day moving average is $1.99.
Hedge Funds Weigh In On Immix Biopharma
An institutional investor recently bought a new position in Immix Biopharma stock. Jane Street Group LLC bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned 0.06% of Immix Biopharma at the end of the most recent reporting period. 11.26% of the stock is currently owned by institutional investors.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
See Also
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
